JP2011507857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507857A5 JP2011507857A5 JP2010539513A JP2010539513A JP2011507857A5 JP 2011507857 A5 JP2011507857 A5 JP 2011507857A5 JP 2010539513 A JP2010539513 A JP 2010539513A JP 2010539513 A JP2010539513 A JP 2010539513A JP 2011507857 A5 JP2011507857 A5 JP 2011507857A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fibrosis
- connexin
- polynucleotide
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 43
- 108091033319 polynucleotide Proteins 0.000 claims description 35
- 102000040430 polynucleotide Human genes 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 206010016654 Fibrosis Diseases 0.000 claims description 22
- 230000004761 fibrosis Effects 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 21
- 208000006111 contracture Diseases 0.000 claims description 16
- 206010062575 Muscle contracture Diseases 0.000 claims description 13
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 102000001045 Connexin 43 Human genes 0.000 claims description 8
- 108010069241 Connexin 43 Proteins 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000000185 Localized scleroderma Diseases 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 201000002793 renal fibrosis Diseases 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000012260 Accidental injury Diseases 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 2
- 206010014664 Endocardial fibrosis Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000001055 Ischemic Contracture Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 206010027982 Morphoea Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- 206010031023 Oral submucosal fibrosis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 201000000027 Volkmann contracture Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 231100000012 chronic liver injury Toxicity 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 102000048481 human GJA1 Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000016809 linear scleroderma Diseases 0.000 claims description 2
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- 206010065988 nodular fasciitis Diseases 0.000 claims description 2
- 208000005207 oral submucous fibrosis Diseases 0.000 claims description 2
- 208000030346 palmar fibromatosis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 201000006081 pseudosarcomatous fibromatosis Diseases 0.000 claims description 2
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 201000004409 schistosomiasis Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 206010056375 Bile duct obstruction Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US879507P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/014021 WO2009085270A2 (en) | 2007-12-21 | 2008-12-22 | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507857A JP2011507857A (ja) | 2011-03-10 |
| JP2011507857A5 true JP2011507857A5 (enExample) | 2013-04-25 |
Family
ID=40824955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539513A Pending JP2011507857A (ja) | 2007-12-21 | 2008-12-22 | 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8975237B2 (enExample) |
| EP (1) | EP2237786A2 (enExample) |
| JP (1) | JP2011507857A (enExample) |
| AU (1) | AU2008343841A1 (enExample) |
| CA (1) | CA2710380A1 (enExample) |
| WO (1) | WO2009085270A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573131B (zh) | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| CA2710380A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions |
| US20110275574A1 (en) * | 2009-01-16 | 2011-11-10 | Agency For Science, Technology And Research | Method of inhibiting proliferation of hepatic stellate cells |
| EP2563923A4 (en) * | 2010-04-28 | 2014-12-17 | Sandeep Kathju | COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS |
| GB201119089D0 (en) * | 2011-11-04 | 2011-12-21 | Isis Innovation | Treatment of musculoskeletal fibroproliferative disorders |
| MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
| JP2015513905A (ja) | 2012-03-27 | 2015-05-18 | コーダ セラピューティクス， インコーポレイテッド | カドヘリン調節に基づく組成物および処置 |
| US10036015B2 (en) | 2013-01-04 | 2018-07-31 | Sandeep Kathju | Composition and methods for reduced scarring and treatment of fibrosis |
| WO2016029191A2 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| CA3050082A1 (en) | 2016-04-04 | 2017-10-12 | Omeza LLC | Fish oil topical composition |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| MX429166B (es) * | 2020-08-12 | 2025-11-13 | Aspid S A De C V | Uso de colageno-polivinilpirrolidona en la inflamacion y fibrosis pulmonar en pacientes infectados por el virus sars-cov2 (covid-19) |
| US12138293B2 (en) | 2020-10-22 | 2024-11-12 | Xequel Bio, Inc. | Peptide formulations and ophthalmic uses thereof |
| US12667586B2 (en) | 2023-03-07 | 2026-06-30 | Glaukos Corporation | Treatments for ocular surface disorders |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| JPH0539594Y2 (enExample) * | 1988-08-05 | 1993-10-07 | ||
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| GB9425930D0 (en) | 1994-12-22 | 1995-02-22 | Procter & Gamble | Silicone compositions |
| US6752987B1 (en) * | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| EP0950060A4 (en) | 1996-12-02 | 2000-07-05 | Dyad Pharmaceutical Corp | COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES |
| US6458590B1 (en) * | 1997-08-07 | 2002-10-01 | The United States Of America, As Represented By The Department Of Health And Human Services | Methods and compositions for treatment of restenosis |
| WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US7098190B1 (en) * | 1999-01-27 | 2006-08-29 | Coda Therapeutics Ltd. | Formulations comprising antisense nucleotides to connexins |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| AU2002213346B2 (en) * | 2000-10-18 | 2006-05-11 | Children's Medical Center Corporation | Osteopontin-coated surfaces and methods of use |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| JP2005509621A (ja) * | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにｅｄｈｆ |
| CN1939529A (zh) * | 2002-01-29 | 2007-04-04 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
| JP2005523326A (ja) | 2002-04-22 | 2005-08-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | プロテインキナーゼｃのペプチドインヒビター |
| WO2003096981A2 (en) * | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| WO2004021861A2 (en) * | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1514929A1 (en) | 2003-09-12 | 2005-03-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| CN1922320B (zh) | 2003-12-03 | 2013-04-24 | 科达治疗（新西兰）有限公司 | 靶向连接蛋白的反义化合物及其使用方法 |
| EP1827480B1 (en) | 2004-12-21 | 2016-11-09 | MUSC Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| CN101573131B (zh) * | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| FR2887524A1 (fr) * | 2005-06-23 | 2006-12-29 | 1 4 Vin Sarl | Moyen d'inertage a faible vitesse et dispositif mettant en oeuvre ce moyen d'inertage pour conditionner un produit alimentaire |
| CA2632876A1 (en) * | 2005-12-16 | 2007-06-21 | Arla Foods Amba | Bovine osteopontin formulations for the improvement of the wound healing process |
| CA2651784C (en) | 2006-05-19 | 2015-01-27 | Mako Surgical Corp. | Method and apparatus for controlling a haptic device |
| RU2542471C2 (ru) * | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Улучшенные способы и композиции для заживления ран |
| PL2101791T3 (pl) | 2006-12-11 | 2015-04-30 | Coda Therapeutics Inc | Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia |
| EP2114422A1 (en) * | 2007-03-02 | 2009-11-11 | National University of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| AU2008335717A1 (en) | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| CN102920996A (zh) | 2007-12-11 | 2013-02-13 | 科达治疗公司 | 受损伤口愈合的药物组合物 |
| EP2252690A2 (en) | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| CA2710380A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions |
| JP2011507860A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス， インコーポレイテッド | 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用 |
| AU2008343840A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
| EP2234656A2 (en) | 2007-12-21 | 2010-10-06 | Coda Therapeutics, Inc. | Improved medical devices |
| AU2008343754A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
| EP2237796A2 (en) | 2007-12-21 | 2010-10-13 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions |
| EP2237795A2 (en) | 2007-12-21 | 2010-10-13 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
| US20110243964A1 (en) | 2007-12-21 | 2011-10-06 | Bradford James Duft | Treatment of orthopedic conditions |
| WO2009097077A2 (en) | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| WO2009148613A1 (en) | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
-
2008
- 2008-12-22 CA CA2710380A patent/CA2710380A1/en not_active Abandoned
- 2008-12-22 JP JP2010539513A patent/JP2011507857A/ja active Pending
- 2008-12-22 EP EP08866327A patent/EP2237786A2/en not_active Withdrawn
- 2008-12-22 WO PCT/US2008/014021 patent/WO2009085270A2/en not_active Ceased
- 2008-12-22 US US12/809,886 patent/US8975237B2/en not_active Expired - Fee Related
- 2008-12-22 AU AU2008343841A patent/AU2008343841A1/en not_active Abandoned
-
2015
- 2015-03-09 US US14/642,582 patent/US9738892B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Donohue et al. | Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD | |
| JP6688224B2 (ja) | Ｍｄｍ２を阻害する手段の投与による関節における変形性関節症の処置 | |
| Figueiredo et al. | The GluK1 (GluR5) kainate/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| CN108738310A (zh) | 用于治疗肌营养不良的方法 | |
| JP2017222691A (ja) | 多発性硬化症を治療するための高投与量ラキニモドの使用 | |
| Blumenthal et al. | The HALTS trial–halting atherosclerosis or halted too early | |
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| KR20120050473A (ko) | 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 | |
| JP2011529958A (ja) | 脳卒中または一過性脳虚血発作を予防するための薬物を調製するためのドロネダロンの使用 | |
| JP2012518019A5 (enExample) | ||
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| DE60021360T2 (de) | Vegf angiogenische wachstumsfaktoren zur behandlung von peripherer neuropathie | |
| KR20110026421A (ko) | 심장율동전환의 예방을 위한 드로네다론 | |
| EP2958572B1 (en) | Treatment of hyperhidrosis | |
| KR20230088810A (ko) | 마이크로rna-29 화합물, 조성물 및 요법에서의 용도 | |
| JP2011519946A (ja) | １−メチルニコチンアミド類似体 | |
| JP2012502105A5 (enExample) | ||
| WO2020201444A1 (en) | Repurposing small molecules for senescence-related diseases and disorders | |
| Kumar et al. | Cilostazol: a new drug in the treatment intermittent claudication | |
| KR20260061479A (ko) | 식도 협착 억제제 | |
| AU2019377275A1 (en) | Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a) | |
| CN111000847B (zh) | 一种治疗肺纤维化的药物制剂及其用途 | |
| CN106999449B (zh) | 用于治疗多汗症的方法 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 |